|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||39.46 - 42.06|
|52 Week Range||39.34 - 107.69|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||87.50|
Subscribe to Yahoo Finance Plus to view Fair Value for CSTLLearn more
Four Houston-area companies made Inc. magazine's inaugural Best-Led Companies in America list. The list highlights 250 companies throughout the U.S. with revenue between $50 million and $2 billion.
FRIENDSWOOD, Texas, November 24, 2021--Castle announced oral presentations on its DecisionDx® skin cancer tests at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting.
Derek Maetzold, Insider at Castle Biosciences (NASDAQ:CSTL), made a large buy and sell of company shares on November 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Derek Maetzold exercised options to purchase 31,815 Castle Biosciences shares at prices ranging from $2.36 to $3.72 per share for a total of $96,040 on November 16. They then sold their shares on the same day in the open market. They sold at prices ranging